Rheumatology
1011 – 1020 of 1579
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
(
- Contribution to journal › Article
-
Mark
The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE.
(
- Contribution to journal › Article
-
Mark
Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics.
(
- Contribution to journal › Article
-
Mark
Pain, fatigue and hand function closely correlated to work ability and employment status in systemic sclerosis.
(
- Contribution to journal › Article
-
Mark
Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis
(
- Contribution to journal › Article
- 2009
-
Mark
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study
(
- Contribution to journal › Article
-
Mark
C1q Inhibits Immune Complex-Induced Interferon-alpha Production in Plasmacytoid Dendritic Cells A Novel Link Between C1q Deficiency and Systemic Lupus Erythematosus Pathogenesis
(
- Contribution to journal › Article
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article
-
Mark
Proteoglycans and more--from molecules to biology.
(
- Contribution to journal › Scientific review
-
Mark
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
(
- Contribution to journal › Scientific review